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Abstract
Epidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies, including pancreatic
cancer, breast cancer, colon cancer, and non–small cell lung cancer. Overexpression of EGFR is a predictive marker
of therapeutic response and several lines of evidence suggest that EGFR is an excellent target for tumor therapy.
However, the effective antitumor capacity of EGFR-specific T cells against EGFR-overexpressing tumor cells has not
been fully elucidated. In our previous study, we identified an anti–EGFR single-chain variable fragment (scFv) with
specific and high affinity after screening by ribosome display. In this study, the anticancer potential of anti–EGFR
scFv was investigated on the basis of cell-targeted therapy. A chimeric antigen receptor (CAR) targeting EGFR was
constructed and expressed on the cell membrane of T lymphocytes. These CAR-modified T cells demonstrated
antitumor efficacy both in vitro and in vivo. In addition, the safety evaluation showed that CAR-modified lympho-
cytes have no or very minimal acute systemic toxicity. Taken together, our study provided the experimental basis for
clinical application of genetically engineered lymphocytes; moreover, we also evaluate a new and interesting cell
therapy protocol.
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Introduction
The epidermal growth factor receptor (EGFR) is overexpressed on
the surface of the cell membranes in a wide variety of solid tumors,
particularly in non–small cell lung cancer (NSCLC). Overexpression
of EGFR has marked effects on various aspects of carcinogenesis, like
cell growth and invasion, angiogenesis, and metastasis. The potential
value of EGFR as a target for the diagnosis and therapy of human
tumors has been recognized for several years [1–4]. A number of
targeting agents directed at tumors that express high levels of EGFR
have been approved for clinical use of treating NSCLC, and antibody
therapy plays an important role in these agents [5,6]. Monoclonal
antibodies (mAbs), such as cetuximab, have shown promising results
in providing a survival advantage for advanced-stage NSCLC patients
[7–10]. However, due to EGFR mutations and the poor penetration
of antibodies into the tumor tissue, these agents are not able to kill a
sufficient number of malignant cells and cause tumor regression
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[11,12]. It is necessary to direct the antibody with a cytotoxic agent
to the target to enhance the efficacy of its antitumor activity.
Adoptive cell therapy (ACT) is a new cancer therapy strategy that
is usually approached through infusion of antitumor immune effec-
tor cells to obtain or enhance antitumor responses in patients.
Dr Rosenberg initiated the prelude of ACT in 1985 when he treated
melanoma with lymphocyte-activated killer cells for the first time
[13]. Many tumor-specific antigen T cell receptor (TCR) genes, such
as the melanoma antigen tumor-specific TCR gene, have been iso-
lated and identified along with the rapid development of genetic
engineering technology in recently years [14–18]. Furthermore, chi-
meric antigen receptor (CAR) technology has combined both the
specificity of mAbs and the efficient cytotoxic of T lymphocytes.
The biggest advantage of CAR is that it is not subject to major
histocompatibility complex (MHC) restriction, as natural TCR is.
Nonspecific lymphocytes can be endowed with the ability to spe-
cifically recognize tumor antigens and to release cytokines by CAR
gene transfection [19,20]. Using this approach in the clinical treat-
ment of a variety of tumors, such as lymphoma [21,22], neuroblas-
toma [23], and metastatic renal cell carcinoma [24], has yielded
encouraging results.
In our previous study, after screening by ribosome display, we
generated an anti-EGFR single-chain variable fragment (scFv) with
high antigen specificity and affinity [25]. An rGel-based EGFR-
specific immunotoxin was constructed, expressed, and purified; this
immunotoxin resulted in significant antigen specificity and anti-
tumor effect both in vitro and in vivo. Here, we aimed to further
investigate the antitumor potential of the anti–EGFR scFv using
the cell-targeted therapy strategy, with a view to establishing whether
the CAR-modified T lymphocytes have potential for application in the
treatment of EGFR-positive carcinoma. To this end, the CAR was
constructed to consist of the human interleukin-2 (IL-2; hIL-2) signal
peptide, anti–EGFR scFv, hemagglutinin (HA) tag, IgG2 Fc, and the
transmembrane region and part of the cytoplasmic region of the
human CD28 signaling chain fused to the cytoplasmic region of
CD3ζ chain. Then, the CAR gene was cloned into the NheI and
BglII sites of a CMV promoter–based nonviral vector, pmaxCloning.
After verification of the expression of the CAR on the cell membrane
of T lymphocytes, the antitumor effects of CAR-modified T cells
were evaluated both in vitro and in vivo. The systemic acute toxicity
of this strategy was also evaluated.
Materials and Methods
Cell Lines and T Cells
Human epithelial carcinoma cell line A431, human NSCLC cell
line A549, human Burkitt’s lymphoma cell line Raji, and human
ovarian cancer cell line A2780 were obtained from American Type
Culture Collection (Manassas, VA). A549, A2780, and Raji cell lines
were cultured in RPMI 1640 (Invitrogen, Grand Island, NY) supple-
mented with 10% heat-inactivated FBS. The A431 cell line was
maintained in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with 10% FBS.
Human T cells were isolated from peripheral blood of healthy
donors under an Institutional Review Board–approved protocol
(95-054), using BD Vacutainer CPT tubes (Becton Dickinson,
Franklin Lakes, NJ) following the manufacturer’s instructions. T cells
were cultured in RPMI 1640 supplemented with 300 IU/ml IL-2
(Novartis Pharmaceuticals, Shanghai, China) and stimulated with
anti-CD3 and anti-CD28 mAbs.
Mice
Five- to six-week-old female nonobese diabetic/severe combined
immunodeficiency (NOD/SCID) CB-17 mice were purchased from
Beijing HFK Bio-Technology Co, Ltd (Beijing, China). Animals
were kept in a specific pathogen-free facility at the Animal Experi-
mental Center of Sichuan University (Sichuan, China). All animal
studies were performed in accordance with the Institutional Animal
Care guidelines.
CAR Construction
The CAR constructs used in this study are schematically illustrated
in Figure 1A, using an assembly technique as follows. Generation of
the anti-EGFR-scFv DNA has recently been described in detail [25].
The hIgG2-Fc fragment was subcloned by polymerase chain reaction
(PCR) from pFUSE-hIgG2-Fc1 plasmid (InvivoGen, San Diego,
CA). The fused CD28 transmembrane region and a part of its intra-
cellular region and CD3-ζ molecules were synthesized by the
GenScript company. Several genetic fragments were assembled by
overlapping PCR, in which the signal peptide of hIL-2 and an HA
tag was also introduced through the forward primer. The expression
cassettes were subcloned into the NheI and BglII sites of pmaxCloning
vector. The sequence of the whole genetic fragment was confirmed by
direct sequencing. The vehicle construct contained the same com-
ponents in similar configuration and order, except that it lacked the
anti–EGFR scFv sequence.
Antigen-specific Cytotoxicity and Cytokine Secretion by
CAR-Modified T Cells
The cytolytic activity of CAR-modified T cells was measured by
assays of lactate dehydrogenase (LDH) release after 6 hours using a
Cytotoxicity Detection Kit (Promega, Madison, WI) according to
the manufacturer’s instructions. The capacity of modified T cells
to produce cytokines [interferon-γ (IFN-γ), granulocyte-macrophage
colony-stimulating factor (GM-CSF), IL-2, and IL-4] was deter-
mined by ELISA Kit in supernatants after 24 hours of incubation
with EGFR-positive cells (Neobioscience, Shenzhen, China).
Mouse Models
Tumorigenicity model. CAR-transfected lymphocytes and A549
tumor cells were washed with serum-free, antibiotic-free medium and
the cell concentrations were adjusted to 2 × 108/ml and 2 × 107/ml,
respectively. Ten mice per group were used and each mouse was inocu-
lated subcutaneously (s.c.) in the scapular region with lymphocyte/
tumor cell mixture in 100 μl of serum-free, antibiotic-free medium at
a ratio of 10:1. All animals weremonitored for a total of 60 days; animals
were weighed and observed for clinical signs every 3 days. The tumor
volume was estimated using two measurements of the nodules, with
the formula V = 0.52 × length × width2.
S.c. model. Log-phase A431 or A2780 cells (5 × 106 cells per
mouse) were injected s.c. into the scapular region. Once tumors were
grown to 200 to 500 mm3 in size, animals were administered CAR-
modified T cells [1 × 107 cells per mouse; intravenously (i.v.)
through the tail vein] at 24, 48, and 72 hours after mice were grouped.
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Lung metastasis model. A549 cells (2 × 106 cells) were administered
i.v. to mice on day 0. Then, tumor-bearing mice were randomly
assigned to one of the four groups: 1) mice treated with normal saline
(NS), 2) mice treated with Mock T cells, 3) mice treated with Vehicle
T cells, and 4) mice treated with CAR T cells. CAR-modified T cells
(2 × 106) were administered i.v. at days 3, 6, 9, 12, 15, and 18 after
tumor injection. Five mice per group were sacrificed at day 30, and the
lung metastasis index of each group was statistically determined as
described in our previous report [26].
Analysis of Toxic Effects Induced by
Systemic Administration in Mice
NOD/SCID mice (five mice per group) were studied for evidence
of acute toxic effects induced by a single i.v. injection of CAR-
modified T cells (2 × 107 cells per mouse). Forty-eight hours later,
the mice were sacrificed and serum was separated. Some of the mice
from the lung metastasis model were also sacrificed 48 hours after the
last cell administration, and serum was separated. Levels of alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) were
measured at the Biochemistry Laboratory in the National Chengdu
Center for Safety Evaluation of Drugs (Chengdu, China). After
sacrifice of the mice in the lung metastasis model at 30 days, the
heart, liver, spleen, and kidney tissues were used for morphologic
analysis and hematoxylin and eosin (H&E) staining.
Statistical Analysis
All statistical analyses were performed using SPSS 19.0 software.
Data are presented as means ± SD. Statistical analysis was performed
Figure 1. Construction and expression of the EGFR-specific CAR in transduced human T lymphocytes. (A and B) Schematic represen-
tation of the construction of EGFR-specific CAR. This CAR consisted of the hIL-2 signal peptide, anti–EGFR scFv, HA tag, IgG2 Fc, the
transmembrane region, and part of the cytoplasmic region of the human CD28 signaling chain, fused to the cytoplasmic region of the
CD3ζ chain. This CAR gene was cloned into NheI and BglII sites of a CMV promoter–based nonviral vector, pmaxCloning. (C) Western
blot analysis of CAR expression in T lymphocytes at 16 hours after transduction. PVDF membranes were labeled with an anti-human
CD3ζ antibody and a goat anti-rabbit IgG HRP-conjugated second antibody. (D) Flow cytometric analysis of CAR expression in T lym-
phocytes at 16 hours after transduction. The transduced cells were stained with anti–EGFR scFv antiserum and goat anti-rabbit IgG
FITC-conjugated secondary antibody and were then detected by a BD FACSCalibur flow cytometer. MFI is the abbreviation of mean
fluorescence intensity. Results are representative of three experiments.
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using Student’s t test for comparing two groups and by analysis of
variance for multiple group comparisons. P values less than .05 were
considered statistically significant.
Results
Efficient Generation of CAR-Modified T Cells Using a
Nucleofection Gene Transfer System
To investigate the therapeutic potential of primary human T lym-
phocytes genetically modified to recognize and kill tumors that
express EGFR, an EGFR-specific single-chain antibody sequence
was selected due to its excellent specificity and binding affinity, as
shown in our previous report [25]. In this study, an EGFR-based
CAR, consisting of scFv of mAb 108 linked to CD28 and CD3 sig-
naling moieties, was constructed and cloned into a nonviral vector,
pmaxCloning (Figure 1, A and B). On the basis of the protocol of the
Nucleofector System (Lonza, Walkersville, MD), optimized nuclear
transfer of lymphocytes was performed in a preliminary experiment.
We found that the best balance between transfection efficiency and
cell survival could be achieved using 8 × 106 T cells and 3 μg of plas-
mid per electroporation cuvette and the T-23 program (data not
shown). This method was thus used in the subsequent experiments.
The expression of the CAR was first confirmed by staining with
anti-CD3ζ antibody in Western blot analysis. As shown in Figure 1C ,
a protein of the expected molecular mass (80 kDa) was detected. The
surface expression of the CAR on T cells was further identified by stain-
ing with anti–EGFR scFv serum. Cells were then analyzed by flow
cytometry; we found that only 1.19% and 1.3% of the cells showed
binding of anti–EGFR scFv serum, while 32.05% of T cells expressed
the CAR (Figure 1D).
Functional Characterization of Anti-EGFR CAR-Expressing
Primary Human T Cells
To determine whether CAR-modified lymphocytes could specifi-
cally target and kill tumor cells, we first determined the expression of
EGFR in several cell lines using flow cytometry, employing staining
with the anti-EGFR antibody. Two EGFR overexpression cell lines
(A431 and A549) and two EGFR-negative cell lines (A2780 and
Raji) were selected for use in the subsequent experiments (Figure 2A).
To investigate whether the CAR-modified T cells were capable of
Figure 2. Cytokine production triggered by EGFR-specific CAR. (A) The expression of EGFR of four tumor cells was detected by flow
cytometric analysis. A431, A549, A2780, and Raji cells were washed once by phosphate-buffered saline and then incubated with anti-
EGFR primary antibody and goat anti-rabbit IgG FITC-conjugated antibody. (B) CAR-modified T lymphocytes were cultured with A431,
A549, A2780, and Raji tumor cells for 24 hours. Supernatants were harvested and the production of IFN-γ, GM-CSF, IL-2, and IL-4 were
detected by ELISA. Results were expressed as means ± SD of triplicate samples and representative of three experiments (*P < .01).
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specifically recognizing tumor cells, a panel of tumor cell lines and
the amount of secreted effector cytokines, IFN-γ, GM-CSF, IL-2,
and IL-4, were determined. The CAR-modified T cells produced
high levels of Tc1 cytokines IFN-γ, GM-CSF, and IL-2 as well
as the Tc2 cytokine IL-4 when they were co-cultured with EGFR-
overexpressing tumor cells, whereas the CAR-modified T cells co-
cultured with EGFR-negative tumor cells showed no significant
cytokine secretion. In addition, the mock-treated (Mock) and vehicle-
treated (Vehicle) T cells co-cultured with either EGFR-overexpressing
or EGFR-negative tumor cell lines secreted no measurable cytokines
(Figure 2B).
The cytotoxicity of CAR-modified lymphocytes was next evaluated
by an LDH release assay. As shown in Figure 3, A to D, the CAR-
modified T cells were able to lyse A431 and A549 tumor cells but not
A2780 and Raji cells. Down-regulation of EGFR expression in A549
cells by siRNA was also performed to consequently verify the EGFR-
mediated killing by CAR T cells. In addition, the results showed that
cytotoxicity of CAR-modified lymphocytes was significantly de-
creased in EGFR silencing A549 cells (Figures W1 and 3E ). The
apoptosis staining was used to visualize the binding capacity of
CAR-modified lymphocytes to tumor cells and the killing of tumor
cells depending on EGFR expression. Sixteen hours after the co-
incubation with T lymphocytes, apoptosis or already dead A549 cells
were identified by propidium iodide (PI) staining. The ratio of apop-
totic and necrotic EGFR silencing A549 cells decreased significantly
compared with normal A549 cells after the treatment of CAR T cells
(Figure W2A). To quantitatively measure cell apoptosis, the cells are
double stained with annexin V and PI. The annexin V–positive and
PI-negative A549 cells were also obviously reduced when EGFR was
silenced (Figure W2A). Taken together, the above data showed that
CAR-modified T cells could effectively mediate antigen-specific cyto-
kine release and cytolytic activity.
T cell proliferative ability is also a very important aspect for the
antitumor immune response, in addition to their cytotoxicity and
cytokine production. In vitro expansion of lymphocytes was per-
formed to determine whether CAR-modified T cells retained the
same cell proliferative ability as control T cells. About 50-fold expan-
sion of CAR-modified T cells could be achieved under standard cul-
ture conditions on day 12 (Figure 4A). Next, we assessed whether the
proliferation of CAR-modified T cells was an antigen-dependent or
antigen-independent effect in vitro. As shown in Figure 4B, CAR-
modified T cells exhibited significantly greater proliferation com-
pared to Mock and Vehicle T cells after stimulation with A431 cells.
However, no significant proliferation was observed when these dif-
ferent T cells were stimulated with EGFR-negative A2780 cells
(Figure 4C ). Another experiment was designed to verify whether
CAR-modified T cells could also retain favorable proliferation in vivo.
Three weeks after establishment of an A549 lung metastasis tumor
model in NOD/SCID mice, the same numbers of Vehicle and
CAR-modified T cells were i.v. co-injected. The sequences of the
vector and anti–EGFR scFv were used to monitor the persistence of
these cells. The results suggested that CAR-modified T cells had a
higher in vivo persistence than Vehicle T cells (Figure 4D).
Evaluating Antitumor Responses of CAR-Modified Human
Primary T Cells In Vivo
The in vivo antitumor efficacy of CAR-modified T cells was first
evaluated in an A431 tumorigenicity model. Animals were monitored
Figure 3. Cytotoxicity of the EGFR-specific CAR to EGFR overexpression tumor cells. (A–D) The CAR-modified T cells were co-cultured
with A431, A549, A2780, or Raji tumor cells at various effector-to-target (E:T) ratios at 37°C for 6 hours. The cytotoxicity of CAR-modified
T cells to target cell lysis was assessed by LDH release assay. Results were expressed as means ± SD of triplicate samples and were
representative of three experiments. (E) Decreased cytotoxicity of the CAR to EGFR silencing A549 cells. A549 cells were transfected
with EGFR siRNA using Lipofectamine 2000 reagent following the manufacturer’s instruction for 24 hours. The cytotoxicity of CAR-
modified T cells to EGFR silencing A549 cells was performed similarly as in A to D.
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for a total of 60 days after co-inoculation of lymphocyte/tumor cell
mixture. The mice infused with CAR-modified lymphocytes
displayed a smaller tumorigenic proportion and lower tumor growth
(Figure 5A). The tumor volume of the mice treated with CAR-
modified lymphocytes was only half of that of the control groups
on day 60 (Figure 5, B and C ). The antitumor activity of CAR-
modified T cells against an established A431 and A2780 s.c. tumor
model was next evaluated. The mice were administered (i.v. through
tail vein) CAR-modified T cells at days 23, 24, and 25, when tumors
had grown to 200 to 500 mm3 in size. A431 tumor–bearing mice
treated with CAR-modified T cells showed significant inhibition of
tumor growth and prolonged survival of animals compared with mice
treated with Mock and Vehicle T cells (Figure 5, D and E ). In con-
trast, all of the mice treated with Mock, Vehicle, and CAR-modified
T cells showed no specific antitumor effect above that observed with
NS in A2780 tumor model (Figure 5, F and G ).
Advanced tumor is usually combined with occasional metastatic
spread to the lung. A xenogeneic model of advanced lung meta-
static A549 cancer was established through tail vein injection to eval-
uate the functional activity of CAR-modified T cells. CAR-modified
T cells were administered at days 3, 6, 9, 12, 15, and 18 after tumor
injection (Figure 6A). As shown in Figure 6, B and C , A549-derived
tumor lung metastasis was significantly decreased when mice were
treated with CAR-modified T cells. The mice treated with CAR-
modified T cells had a very low tumor metastasis index (P < .05 com-
pared with all other groups), whereas the majority of mice treated
with NS or Mock or Vehicle T cells had a higher tumor index (Fig-
ure 6C ). Lung weights were also significantly different (P < .05)
between mice treated with CAR-modified T lymphocytes and the
other control groups (Figure 4D).
Analysis of Toxic Effects Induced by
Systemic Administration in Mice
Systemic toxic effects in the mice were evaluated to characterize
whether treatment with CAR-modified T lymphocytes is safe in pre-
clinical experiments. Single doses of 2 × 107 CAR-modified T cells
per mouse were given by tail vein injection. Blood samples were col-
lected from the mice after treatment, and serum levels of liver AST
and serum ALT were measured. However, treatment with CAR-
modified T cells did not increase the levels of AST and ALT, indi-
cating an absence of significant liver toxicity in the mice (Figure 7A).
Some of the mice from the lung metastasis model experiment were
also sacrificed 48 hours after the last T cell administration, and serum
was separated; the same results as in Figure 7A were obtained
(Figure 7B). The results of H&E staining showed that mice treated
with CAR-modified T cells had no pathologic changes in major or-
gans compared with NS mice (Figure 7C ). Collectively, these data
suggested that CAR-modified T cells have no or only minimal sys-
temic acute toxicity.
Discussion
The long-term goal of tumor immunotherapy is to enhance the tar-
geting ability of the immune system to the cancer antigen. However,
this is very challenging, because most tumor-specific antigens are au-
tologous proteins and have a low immunogenicity. Moreover, tumors
Figure 4. Proliferation characteristics of EGFR-specific CAR-modified T cells. (A) In vitro expansion of human T lymphocytes following
different transduction conditions. Twelve hours after nucleofection, exogenous IL-2 was added to the cultures, every other day, at
300 IU/ml. Data are representative of three separate experiments. (B and C) In vitro expansion of CAR-modified T lymphocytes with
antigen-dependent effect. CAR-modified T lymphocytes were cultured under the same condition just as in A. Cultures were restimulated
with either A431 cells (B) or A2780 cells (C) at 7 days. Positive T cells were stained with anti–HA tag antibody and counted by flow
cytometry. Data are representative of at least two separate experiments. (D) In vivo persistence of EGFR-specific CAR-modified T cells.
The same numbers of Vehicle and CAR T cells were co-injected (i.v.) into NOD/SCID mice bearing a A549 lung metastasis model. The
number of copies of Vehicle and CAR vectors in the spleen DNA from mice was evaluated, at various times following T cell injection, by
quantitative PCR. Bars, means ± SD.
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can also downregulate the expression of the MHC and immunosup-
pressive molecules and cytokines to escape the attacks of the immune
system [27]. To overcome this difficulty, many researchers have tried
a variety of immunotherapeutic strategies, including tumor vaccine
[28,29], mAb [30,31], and ACT [15,32]. Genetically modified
T lymphocytes, which can express a CAR to recognize tumor anti-
gens, hold great potential as a treatment strategy in the field of cancer
immunotherapy [33].
Figure 6. CAR-modified T cells inhibit pulmonary metastases in A549 mouse model. NOD/SCID mice received i.v. injections of A549
tumor cells and were randomized into four groups before beginning therapy with CAR-modified T cells. Treatment strategy of A549
tumor–bearing mice as shown in A. (B) Kaplan-Meier survival of tumor-bearing mice. (C–E) Five mice per group were sacrificed at
day 30, and the mean lung metastases index and lung weights of each group were calculated. Bars, means ± SD (*P < .05)
Figure 5. Efficient inhibition of s.c. tumor growth by CAR-modified T cells in vivo. (A–C) The suppression of tumorigenicity of A549 cells
by CAR-modified T cells. CAR-transfected lymphocytes and A549 tumor cells were co-inoculated s.c. at a ratio of 10:1. Tumorigenicity of
the animals was monitored and calculated every 3 days (A). All of the mice were sacrificed and the mean tumor volume was calculated.
Bars, means ± SD (*P< .05) (B and C). (D–G) Inhibition of the tumor growth by CAR-modified T lymphocytes. A431 or A2780 tumor cells
were implanted s.c. into NOD/SCID mice at day 0. Once tumors had grown to 200 to 500 mm3, animals were grouped and i.v. injected
with CAR-modified T cells on days 23, 24, and 25. (D) Tumor volume of A431 tumors. Bars, means ± SD. (E) Survival of animals bearing
A431 tumors. (F) Tumor volume of A2780 tumors. Bars, means ± SD. (G) Survival of animals bearing A2780 tumors.
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In contrast to tumor infiltrating lymphocytes (TIL) or cytokine-
induced killer (CIK), CAR is used to overcome MHC restriction on
the inherent antigen presentation of T lymphocytes. The core part of
this strategy is the generation of genetically modified T lymphocytes.
An effective T lymphocyte must meet the following rigorous condi-
tions: capacity to specifically recognize tumor targets, long time in vivo
persistence, low immunogenicity risk, and it should be easily obtained.
In the present study, we have generated a new kind of EGFR-specific
CAR gene–modified T lymphocytes using a nonviral vector delivered
by nucleofection technology. The results of Western blot and flow cy-
tometry experiments showed that the CAR was efficiently expressed on
the cell membrane.Moreover, this CAR-modified T cells demonstrated
good antitumor effects both in vitro and in vivo, without MHC restric-
tion. Moreover, no marked systemic toxicity was detected during the
treatment process.
The selection of the target antigen is an important aspect for CAR
gene–mediated cell therapy. EGFR is overexpressed on the cell sur-
face of a wide variety of solid tumors [34]. It plays crucial roles in cell
signaling, cell proliferation, regulation of apoptosis and angiogenesis,
and tumor occurrence and development. Several targeting agents di-
rected at tumors that express high levels of EGFR have been ap-
proved for clinical treatment [5,6,35]. Prerequisites for effective
CAR-modified lymphocytes are the target specificity and antigen af-
finity of the scFv. An anti-EGFR single-chain antibody gene was pre-
viously obtained by ribosome display technology, and an anti-EGFR
immunotoxin was generated in our previous study [25]. The recom-
binant anti-EGFR immunotoxin showed high specificity, affinity,
and effective cytotoxicity to EGFR-positive cells, both in vitro and
in vivo. However, higher affinity is not always advantageous because
of the potential toxicity (on target/off tumor) to normal tissue. The
EGFR antigen is also weakly expressed in some normal tissues. If the
affinity of the anti–EGFR scFv is too high, CAR-modified lympho-
cytes may bind to normal tissues before it arrives at the tumor tissue
and thus cause serious side effects [22,36,37]. Therefore, we have
examined the potential systemic toxicity of CAR-modified lympho-
cytes; our results showed that it may be a safe tumor therapy strategy.
In vivo persistence of CAR-modified lymphocytes has also great
impact on therapy efficacy, in addition to targeting specificity. Injec-
tion or expressions of cytokines, immune clearance, and addition of
gene fragments that can extend the life of CAR-modified T lympho-
cytes to the intracellular domain of CAR have been used extensively.
Several researchers have reported that IL-2, IL-7, IL-15, and IL-21
could improve in vivo persistence and antitumor effects [38–41].
However, expression of these cytokines will be regulated by many
factors, such as Treg cells [42]. It is hard to judge to what extent
these cytokines will promote tumor therapeutic efficacy. In the pres-
ent study, IL15 was designed to be co-expressed with the CAR in the
T lymphocytes. However, this strategy did not significantly improve
the therapeutic effectiveness of CAR-modified lymphocytes. In addi-
tion, some researchers found that Treg cells soon have a marked neg-
ative regulatory effect following injection of therapeutic lymphocytes
[43]. Rosenberg et al. have improved the therapeutic response, to
more than 70%, using a sublethal dose of radiation before applying
ACT. However, many older patients are not able to tolerate sublethal
doses of immune clearance strategies, and high-dose IL-2 can cause
significant side effects, such as renal toxicity [44]. CAR construction
has improved from the first to the third generation in recent years.
Some studies have shown that the first-generation CARs only had
Figure 7. Systemic toxicity evaluation of CAR-modified T cells. (A) Acute toxic effects induced by a single i.v. injection of CAR-modified
T cells (2 × 107 cells per mouse). Forty-eight hours later, the mice were sacrificed and serum was separated. Levels of serum ALT and
AST were measured. Bars, means ± SD. (B and C) Acute toxic effects induced by multiple i.v. injections of CAR-modified T cells. Some
of the mice from the lung metastasis model were sacrificed 48 hours after the last cell administration, and several organs and serum
were separated. (B) Levels of ALT and AST were measured using the same method as in A. Bars, means ± SD. (C) The heart, liver,
spleen, and kidney tissues were used for morphologic analysis and H&E staining (original magnification, ×100).
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basic antitumor effects, and there was insufficient evidence to prove
that the CAR-modified lymphocytes could significantly improve
antigen-mediated cell proliferation. The main design of the second
generation of CARs was the insertion of the CD28 or 4-1BB intra-
cellular signaling domains between the transmembrane region and
the CD3ζ domain. Experimental results have proven that second-
generation CARs can significantly enhance lymphocyte proliferation,
while still maintaining the same antitumor effects as first-generation
CARs [45,46]. Third-generation CARs were produced by connecting
a third intracellular signal component to the second-generation CAR.
These modified CARs can further amplify the signal transduction
triggered by antigen binding by the CAR, thus markedly enhancing
its antitumor effects. However, it also increases the risk in clinical
treatment because of the potential of producing a high level of in-
flammatory cytokines in a short time, termed a “cytokine storm”
[47,48]. On the basis of this concern, we designed the CAR used
in this study following a second-generation approach, hoping in so
doing to keep the balance between sufficient antitumor effects and
low systemic toxicity.
Gene transfection of lymphocytes is also a major problem in
immunology research. The most popular strategy used in transfection
of lymphocytes employs an integrated virus, such as yielded by lenti-
viral and retroviral vectors. These viruses can randomly integrate into
the genome of lymphocytes, which may lead to the activation of some
unknown cancer genes and other disease genes, resulting in a latent
hazard [49]. In this study, we designed the CAR construct using a
nonviral vector and achieved efficient transfection efficiency using
the Nucleofector System after optimizing the electric transfer param-
eters. Cell viability could be maintained at more than 85%, and trans-
fection efficiency of lymphocytes achieved was 25% to 35%.
Although there is still a big gap of the transfection efficiency of
nucleofector compared with viral vectors, it is rare in the nonviral vec-
tor system and has a higher safety. The nonviral vector–based CAR in
our study could be continually expressed in vivo in 2 weeks, which
ensured a sufficient time for its antitumor effect (Figure 4D).
Taken together, we have investigated the anticancer ability of the
EGFR-targeting scFv in genetically modified EGFR-targeting lym-
phocytes. The EGFR-targeted CAR-modified T lymphocytes dem-
onstrated specific cytotoxicity and expressed cytokines efficiently
after stimulation with the tumor antigen. Through the recognition
of EGFR, our ACT method directly inhibited tumor formation,
growth, and metastasis, and the CAR-modified lymphocyte treatment
strategy demonstrated good safety. Our study provides an experimental
basis for the clinical application of genetically engineered EGFR-
targeted lymphocytes; moreover, we also evaluated a new and interest-
ing therapy protocol.
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Supplementary Materials and Methods
Antibody
Anti-EGFR and anti-CD3ζ antibodies were purchased from Cell
Signaling Technology (Danvers, MA), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antibody was purchased from Trevigen
(Gaithersburg,MD). To prepare anti–EGFR scFv serum,NewZealand
white rabbits (Laboratory Animal Center of Sichuan University,
Chengdu, China) were immunized s.c. three times with a mixture of
EGFR scFv protein/complete and incomplete Freud’s adjuvant; then,
the rabbits were sacrificed and serum collected and stored at −80°C.
CAR Gene Transduction of Human T Cells
After stimulating with anti-CD3 and anti-CD28 mAbs for 5 days,
human primary T cells were washed once in RPMI 1640 medium
without FBS and were resuspended in 100 μl of nucleofector solution;
3 μg of plasmid DNA (viz., EGFR-specific CAR vector or an equal
amount of the vehicle vector, in moles) was immediately added and
mixed well with the cell solution. The cell/DNA mixture was sub-
sequently transferred to an electroporation cuvette and placed in the
Nucleofector device (Lonza). Nucleofection of the cells was accomplished
using the T-23 program, and samples were immediately transferred to
six-well plates containing 2 ml of prewarmed media without hIL-2. Cells
were incubated in a humidified 37°C/5% CO2 incubator. Medium
that contained IL-2 was changed 12 hours after the transfection.
Detection of CAR Expression on Human T Cells
For Western blot analysis, human T cells transfected with the
CAR construct were lysed in RIPA buffer and the cell lysates were
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis
on a 12% acrylamide gel. Proteins were transferred to a polyvinylidene
difluoride (PVDF) membrane, which was then incubated first with a
rabbit anti-human CD3 zeta antibody and then with a goat anti-rabbit
IgG HRP-conjugated antibody. Antibody binding was revealed using
an Enhanced Chemiluminescent Kit (Santa Cruz Biotechnology Inc,
Santa Cruz, CA).
For flow cytometric analysis, CAR construct–transfected human
T cells were washed once with phosphate-buffered saline and then
incubated with anti–EGFR scFv serum and subsequently with a goat
anti-rabbit IgG fluorescein isothiocyanate (FITC)–conjugated anti-
body. Positive cells were detected using a BDFACSCalibur flow cytom-
eter (BD Biosciences, San Jose, CA).
Competitive In Vivo Persistence Experiment with CAR T Cells
and Vehicle T Cells
Mice were engrafted with 2 × 106 A549 cells, followed 3 weeks
later by escalating doses of a 1:1 mixture of CAR T cells and Vehicle
T cells, after adjusting according to the transfection efficiency. Some
of the animals were sacrificed and spleen samples were collected 0, 7,
14, and 28 days after T cell injection. The biodistribution of the
CAR T cells and Vehicle T cells were investigated using quantitative
PCR for the vector and anti–EGFR scFv sequence.
Figure W1. Down-regulation of EGFR expression in A549 cells by
siRNA. A549 cells were transfected with EGFR siRNA using
Lipofectamine 2000 reagent following the manufacturer’s instruc-
tion for 24 hours. The transfected A549 cells were lysed in RIPA
buffer and separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis on a 12% acrylamide gel. After transfer to a
PVDF membrane, this was incubated with anti-EGFR or anti-
GAPDH primary antibody and goat anti-rabbit IgG HRP-conjugated
second antibody. Antibody binding was revealed by using the
Enhanced Chemiluminescent Kit.
Figure W2. Visualization of the binding capacity and cytotoxicity of CAR-modified lymphocytes to tumor cells. A549 cells were trans-
fected with EGFR siRNA using Lipofectamine 2000 reagent following the manufacturer’s instruction for 24 hours. Then, the A549 cells
were co-incubated with T lymphocytes. (A) Sixteen hours later, apoptosis or already dead A549 cells were identified by PI staining. A549
cells (yellow arrow) with bigger nuclei can be differed from lymphocytes (green arrow; original magnification, ×100). (B) Four hours later,
the cells are double stained with annexin V and PI and detected by flow cytometry.
